Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Biotechnology

Healthcare
$3.77 +1.53%

+$0.10 today

Market cap
$1.22B
Beta
1.18
P/E (TTM)
-17.7
EPS (TTM)
-$0.35
52W Low $2.25High $7.30

Volume 2.17M

Average 2.73M

Income Statement

Follow revenue through to earnings.

Revenue

$9.77M

FY 2025 · Annual

+17.3% YoY

Operating Income

-$110.50M

FY 2025 · Annual

Net Income

-$109.00M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue02.5M15.45M8.33M9.77M
Cost of Revenue02.49M000
Gross Profit015K15.45M8.33M9.77M
Gross Margin—0.6%100.0%100.0%100.0%
Research & Development131.94M91.17M56.78M66M86.4M
Selling, General & Admin41.32M34.87M30.05M28.95M33.87M
Operating Expenses173.27M126.04M87.89M99.79M120.27M
Depreciation & Amortization492K2.49M1.37M1.25M1.15M
EBITDA(172.6M)(159.73M)(105.2M)(87.95M)(107.79M)
EBITDA Margin—-6384.1%-680.8%-1055.5%-1102.9%
Operating Income(173.27M)(126.03M)(72.44M)(91.46M)(110.5M)
Operating Margin—-5037.1%-468.8%-1097.6%-1130.6%
Interest Income172K249K3.57M6.94M9.22M
Interest Expense1.43M3.8M5M102K63K
Other Income / Expenses(1.26M)(39.99M)(39.13M)2.16M1.5M
Income Before Tax(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Pre-Tax Margin—-6635.3%-722.1%-1071.6%-1115.3%
Income Tax Expense00000
Net Income(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Net Margin—-6635.3%-722.1%-1071.6%-1115.3%
EPS (Basic)(4.64)(3.78)(0.96)(0.36)(0.34)
EPS (Diluted)(4.64)(3.78)(0.96)(0.36)(0.34)
Weighted Avg Shares37.65M43.95M116.12M250.13M319.71M
Weighted Avg Shares (Diluted)37.65M43.95M116.12M250.13M319.71M

TSHA Earnings Waterfall · TTM

NASDAQ:TSHA · Revenue to Net Income

Key Ratios

EPS$-0.42
Gross Margin23.6%
Net Margin-126.9%
P/E Ratio-12.1
P/S Ratio80.1

Analysis

$5.5M of revenue converted into -$149.6M of net income for the selected period. Gross margin is 23.6% and net margin is -126.9%, showing how much revenue survives after costs and taxes. EPS is $-0.42, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
SC 13G/ASC 13G/A filingAug 13, 2026
10-QQuarterly reportAug 11, 2026

How much revenue does TSHA generate?

Taysha Gene Therapies, Inc. (TSHA) reported $9.77M of revenue in fiscal 2025.

Is TSHA profitable?

Taysha Gene Therapies, Inc. (TSHA) reported -$109.00M of net income, with a net margin of -1115.3%.